[{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Glycerine","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oil\/Drops","sponsorNew":"Santen Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Curcuma Longa","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Shilpa Medicare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Shilpa Medicare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shilpa Medicare \/ Not Applicable"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"HYDROXYPROPYLMETHYLCELLULOSE","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Alcon Inc \/ Ocumension Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Alcon Inc \/ Ocumension Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals for Glycerine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : OcuMension will acquire outright, Tears Natural Forte, Bion Tears, Alcaine, Fluorescite, and Cyclogyl, in the Chinese market and AR-15512, a novel topical drug candidate for dry eye.

                          Brand Name : Tears Naturale Forte

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 12, 2024

                          Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE,Glycerine,Dextrans

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : OcuMension Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : ORAAL, an oral spray with a naturally derived formulation, which is indicated for the treatment of oral mucositis. The composition of ORAAL is protected by a granted patent in India until November 2033.

                          Brand Name : Oraal

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 13, 2023

                          Lead Product(s) : Curcuma Longa,Glycerine,Propolis

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Cationorm® Plus (glycerol) is a sterile, preservative-free, artificial tear containing the novel Novasorb® technology. As the only artificial tear that uses positive cationic emulsion to hold hydration in place, it protects, hydrates and lubricates the...

                          Brand Name : Cationorm Plus

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 06, 2022

                          Lead Product(s) : Glycerine,Tyloxapol API,Detalan

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank